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ABSTRACT
Background: The optimal treatment of BRCA wild-type patients with platinum-sensitive 
recurrent ovarian cancer remains unknown. Recently, there is an increase in the evidence 
to support the role of the combination of a poly(adenosine diphosphate-ribose) polymerase 
inhibitor, anti-angiogenic agents, and immunotherapy as maintenance therapy in BRCA 
wild-type patients with platinum-sensitive recurrence. We hypothesized that adding 
pembrolizumab and bevacizumab to olaparib maintenance can increase progression-free 
survival (PFS) in BRCA wild-type patients with platinum-sensitive recurrent ovarian cancer.
Methods: BRCA wild-type patients who received two previous courses of platinum-containing 
therapy, achieved complete or partial response to last treatment, and the treatment-free 
interval is >6 months after the penultimate platinum-based chemotherapy offered olaparib 
maintenance with pembrolizumab and bevacizumab. Forty-four patients will be included from 
4 sites across Singapore and Korea. The primary endpoint of the study is 6-month PFS rate.
Trial Registration:  ClinicalTrials.gov Identifier: NCT04361370,  
Clinical Research Information Service Identifier: KCT0005144
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INTRODUCTION
Ovarian cancer remains one of the most lethal gynecological malignancies in women. Most 
women present with advanced-stage cancer and develop recurrence after first-line therapy. 
Platinum-based chemotherapy is the standard of care for patients with platinum-sensitive 
recurrent ovarian cancer, defined as development of recurrence ≥6 months after completing 
first-line chemotherapy. However, repeated exposure to platinum agents can cause toxicity 
and resistance to chemotherapy, leading to death. New therapeutic options for recurrent 
cancer would, therefore, be of clinical interest.
Poly(ADP-ribose) polymerase inhibitors (PARPis) are approved for the treatment of patients 
with ovarian cancer harboring BRCA1/2 mutations, as well as for BRCA1/2-wildtype patients 
with platinum-sensitive recurrent ovarian cancer. The rationale supporting the development 
of PARPis for BRCA1/2-mutant cancers was based on the concept of synthetic lethality, 
which predicated anti-tumor efficacy of PARPis in tumors with defects in homologous 
recombination repair. As maintenance therapy after second-line chemotherapy in a 
platinum-sensitive relapsed setting, three PARPis have demonstrated efficacy in patients 
without BRCA1/2 mutations, although the magnitude of benefit has been consistently much 
smaller compared to that in BRCA1/2-mutant patients. For example, the median progression-
free survival (PFS) improvement in patients with platinum-sensitive relapsed BRCA1/2-mutant 
ovarian cancer treated with olaparib compared to that in patients treated with placebo was 
19.1 months versus 5.5 months (hazard ratio [HR]=0.30; p<0.001), conferring an overall 
survival (OS) benefit of 1 year [1], but in patients with platinum-sensitive relapsed BRCA1/2-
wildtype epithelial ovarian cancer, this was only 8.4 versus 4.8 months (HR=0.35; p<0.001) 
[2], and no OS benefit was seen. Similar results showing the disparity in benefit between 
BRCA1/2-mutated and -wildtype populations were seen in two phase III trials of maintenance 
PARPis therapy, using niraparib [3] and rucaparib [4], separately.
Bevacizumab is another maintenance therapy option for BRCA wild-type patients with 
recurrent ovarian cancer, and its use is supported by the growing clinical experience 
with antiangiogenics in ovarian cancer. In Korea, the Food and Drug Administration has 
permitted bevacizumab therapy for concurrent use and maintenance in all cases of platinum-
sensitive recurrence [5,6]. This is supported by the OCEANS trial [5] and Gynecologic 
Oncology Group (GOG) 213 [6] that evaluated the addition of bevacizumab to chemotherapy 
concurrently and then as maintenance post-chemotherapy until disease progression. In these 
trials, only a 4–6-month improvement was observed in the median PFS after second-line 
chemotherapy even with bevacizumab maintenance. Thus, there is an unmet medical need 
for therapies that, when used in combination with the current standard of care, substantially 
increases the proportion of patients with complete remission and prevents disease 
recurrence in patients with advanced-stage ovarian cancer.
To date, combinations of PARPis + anti-angiogenic therapy, PARPis + programmed cell death 
protein 1 and programmed cell death ligand 1 (PD-1/PD-L1) blockade, and anti-angiogenic 
therapy + PD-1/PD-L1 blockade, have been investigated and shown to be synergistic and 
safe, even in BRCA1/2-wildtype patients. Although clinical trials are ongoing, no published 
studies have described the effect of combination therapy of all three classes of drugs, namely, 
PARPis, anti-angiogenic therapy, and immunotherapy, in recurrent ovarian cancer patients. 
The safety profile of the MEDIOLA combining olaparib, durvalumab and bevacizumab was 
well tolerated in patients with BRCA wild-type platinum-sensitive recurrent ovarian cancer, 
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consistent with the known safety profiles of the single agents. The combination of PARPis, 
PD-L1 and anti-angiogenic therapy is now being tested as part of first-line maintenance 
treatment in the clinical trials, including DUO-O (olaparib, durvalumab, bevacizumab), 
ENGOT-ov43 (olaparib, pembrolizumab, bevacizumab), it is unknown yet whether 
combination of three drugs has synergistic and safe for BRCA wild-type patients. Therefore, 
the OPEB-01 study endeavors to study the combination of olaparib, bevacizumab, and 
pembrolizumab as maintenance therapy in BRCA1/2-wildtype patients with platinum-sensitive 
recurrent ovarian cancer, by leveraging its potential synergy.
METHODS
1. Trial design
This phase II study of olaparib maintenance with pembrolizumab and bevacizumab in 
BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01) 
is a multi-center, investigator-initiated, single-arm study which recruited from four sites 
across Singapore and Korea, with institutional review board approval obtained from each 
site. Patients with recurrent BRCA wild-type ovarian cancer who have responded to their 
last platinum-based chemotherapy (complete or partial response) are offered olaparib, 
pembrolizumab, and bevacizumab as maintenance treatment (Fig. 1). The treatment to be 
used in this trial is outlined in Table 1. Trial treatment will be administered on day 1 of each 
cycle on an outpatient basis. Pembrolizumab (200 mg) will be administered as an intravenous 
infusion for 30 minutes every 3 weeks from cycle 2 onwards.
2. Participants
Patients with the following inclusion criteria will be enrolled in this study and all patients 
must provide informed consent to participate in this study: 1) Histologically confirmed 
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Recurrent BRCA wild-type OC
-   Nonmucionous OC
-   No germline and tumor BRCA mutation
-   ≥6 months after 1st line chemotherapy
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Fig. 1. Study schema. 
CR, complete remission; ECOG, Eastern Cooperative Oncology Group; OC, ovarian cancer; PD, progressive 
disease; PR, partial remission.
Table 1. Trial treatment
Drug Dose/potency Dose frequency Route of 
administration
Regimen/treatment period Use
Pembrolizumab 200 mg Q3W IV infusion Q3W; day 1 of each 3-week cycle from cycle 2 Experimental
Olaparib 300 mg BID Oral During each treatment cycle Experimental
Bevacizumab 15 or 7.5 mg/kg Q3W IV infusion Q3W; day 1 of each 3-week cycle Background therapy
BID, twice daily; IV, intravenous; Q3W, every 3 weeks
diagnosis of high-grade predominantly serous, endometrioid, carcinosarcoma with high-
grade serous component, clear cell, or low-grade serous ovarian cancers, primary peritoneal 
cancer, or fallopian tube cancer (only up to 8 patients with clear cell carcinoma will be 
included); 2) Participant has received two previous courses of platinum-containing therapy 
and has disease that was considered platinum-sensitive following the penultimate (next 
to last) platinum course (more than 6 months of interval between penultimate platinum 
regimen and progression of disease); 3) Participant has responded to the last platinum 
regimen (complete or partial response), remains in response, and is enrolled on study within 
8 weeks after completing the last platinum regimen; 4) Participant is able to provide a newly 
obtained core or excisional biopsy of a tumor lesion for prospective testing of BRCA 1/2 and 
PD-L1 status prior to enrollment; 5) Females aged 20 years or older at the time of acquisition 
of informed consent; 6) Eastern Cooperative Oncology Group performance status of 0–1; 7) 
Participant has adequate organ function; 8) Participant is not pregnant or breastfeeding.
We will exclude patients based on the following criteria: 1) Participant has mucinous, germ 
cell, or borderline tumor of the ovary; 2) Participant has a known or suspected deleterious 
mutation (germline or somatic) in either BRCA1 or BRCA2; 3) Participant has a history 
of non-infectious pneumonitis that required treatment with steroids or currently has 
pneumonitis; 4) Participant either has myelodysplastic syndrome/acute myeloid leukemia 
or features suggestive of myelodysplastic syndrome/acute myeloid leukemia; 5) Participant 
has a known additional malignancy that is progressing or has required active treatment 
within the past 3 years; 6) Participant has known active central nervous system metastases 
and/or carcinomatous meningitis; 7) Participant has a known history of active tuberculosis; 
8) Participant has a known history of Hepatitis B (defined as hepatitis B surface antigen 
reactive) or known active hepatitis C virus (defined as presence of HCV RNA [qualitative]) 
infection; 9) Participant has uncontrolled hypertension, defined as systolic >140 mmHg or 
diastolic >90 mmHg documented by two blood pressure readings taken at least 1 hour apart; 
10) Participant has a history of hemorrhage, hemoptysis, or active gastrointestinal bleeding 
within 6 months.
3. Primary endpoint
The primary endpoint of the study is a PFS rate of 6 months. PFS is defined as the time from 
the start of treatment until the first documented sign of disease progression or death from 
any cause.
4. Secondary endpoints
The secondary endpoints include OS (time frame: up to 1 year), time to progression (time 
frame: up to 1 year), time to first subsequent treatment (or death) (time frame: date of first 
documented subsequent treatment or date of death, assessed up to 72 months), time to 
second subsequent treatment (time frame: date of first documented second subsequent 
treatment assessed up to 72 months), and PFS 2. OS is defined as the time from the first 
treatment until death from any cause.
5. Exploratory endpoints
The exploratory endpoint of this study is to identify molecular biomarkers of clinical 
response/resistance, safety, and/or the mechanism of action of pembrolizumab, olaparib, 
and bevacizumab in platinum-sensitive recurrent ovarian cancer. Comprehensive genomic 
profiling will be performed for all samples to find the predictive biomarkers. Tumors and 
blood samples from this study will be examined to identify BRCA reversion mutation and 
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homologous recombination deficiency status changes. This research will include exome 
sequencing, RNA sequencing, whole genome sequencing, and circulating tumor DNA.
6. Sample size
The sample size was calculated based on Simon's 2-stage optimal design with assumptions 
concerning the estimated PFS rate in ovarian cancer. The rate of patients with disease-
free state at 6 months is expected to be 50% with bevacizumab maintenance (current 
standard of care and results from GOG 213), and the HR of adding maintenance therapy of 
3 combinations (PARPis, antiangiogenic therapy, and immune checkpoint inhibitor) was 
assumed to be 0.5, which was equivalent to 70.7% of PFS rate. When applying the same 
expected efficacy (HR=0.5) with DUO-O study (NCT04361370), the null hypothesis for this 
study will be 50% of the 6-month PFS rate, and alternative hypothesis of interest will be 70% 
of 6-month PFS rate. Using Simon's two-stage optimal design at a one-sided 5% level of 
significance and 80% power, a total of 39 patients are required in this study. In the 1st stage, 
22 patients will be enrolled; if 10 or more progressive disease (PD) are observed, the trial will 
be terminated. If not, the trial will continue to the second stage, and a total of 39 patients will 
be studied. If the total number of PD is less than 15 or equal to, the null hypothesis will be 
rejected. Considering 10% follow-up loss, the sample size will be 44 patients in each dose.
7. Randomization and blinding
Not applicable.
8. Statistical methods
Efficacy analyses are based on the modified intent-to-treat approach (patients should receive 
at least one treatment dose). Safety analyses are based on the safety population (treated 
with at least one dose of study drug). Adverse events are graded according to common 
terminology criteria for adverse events version 5.0. After recruiting 22 patients, interim 
analysis will be conducted to determine futility of the treatment.
DISCUSSION
Recently, several randomized clinical trials on maintenance treatment with PARPis showed 
significant improvement in PFS and OS in patients with platinum-sensitive recurrent ovarian 
cancer and a BRCA mutation (somatic or germline) [1,3,4]. Therefore, such patients are most 
likely to benefit from treatment with PARPis. For BRCA-wildtype patients with platinum-
sensitive recurrent ovarian cancer, few options for maintenance therapy are suggested; 
olaparib, niraparib, and bevacizumab as monotherapies are possible maintenance treatment 
options. Randomized studies comparing maintenance PARPis and placebo have consistently 
shown a smaller degree of benefit for BRCA-wildtype patients compared to BRCA-mutant 
patients. Study19 was a phase II trial of patients with platinum-sensitive recurrent ovarian 
cancer who were treated with at least two prior courses of platinum-based chemotherapy 
and achieved complete or partial response to the last chemotherapy. BRCA-wildtype patients 
treated with olaparib showed greater improvement in PFS compared to those treated with 
placebo; however, the absolute difference between the groups was small (7.4 vs. 5.5 months; 
HR=0.54; p=0.0075). The NOVA trial [3], evaluating niraparib maintenance, included two 
independent cohorts, BRCA-mutation and BRCA-wildtype. BRCA-wildtype group showed 
longer PFS compared to the placebo group; however, the absolute difference between the 
groups was similarly small (9.3 vs. 3.9 months; HR=0.45; p<0.001). Based on the results from 
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GOG 213, median PFS after second-line chemotherapy is 6 months even with bevacizumab 
maintenance. Thus, there is an unmet need for novel therapy for patients with platinum-
sensitive recurrent ovarian cancer without a BRCA mutation.
Novel treatments such as PD-1/PD-L1 immune checkpoint blockade have been investigated in 
recurrent ovarian cancer. The importance of the immune system in ovarian cancer has been 
demonstrated [7], whereby increased presence of tumor-infiltrating lymphocytes correlated 
with improved prognosis. However, immune checkpoint blockade monotherapy has had 
disappointing results, showing low objective response rates of <15% in several trials [8-10]. 
In patients with recurrent ovarian cancer treated with pembrolizumab monotherapy, PFS 
was only 2.1 months [10]. Certain populations may benefit more from immune checkpoint 
inhibitor monotherapy (e.g., PD-L1 positive and/or deficient mismatch repair patients). 
In order to expand current indications for PARPis, immune checkpoint blockade, and 
anti-angiogenics, including their application to biomarker negative patients, combination 
strategies are suggested. In a study of PARPis combined with anti-angiogenic agents, Liu 
et al. showed synergistic effects of olaparib and cediranib in BRCA-wildtype patients [11]. 
The AVANOVA randomized phase II study showed that the combination of niraparib and 
bevacizumab significantly improved PFS better than niraparib alone [12]. This survival 
benefit was more pronounced in non-BRCA mutation and/or homologous recombination 
deficiency negative patients as well as BRCA and/or homologous recombination deficiency 
positive group. The PAOLA randomized phase III study is currently evaluating the synergistic 
effects of olaparib and bevacizumab [13]. In PARPis with immune checkpoint inhibitor, 
PARPis treatment led to an accumulation of cytosolic dsDNA, which activates the cGAS-
STING-TBK1-IRF3 innate immune axis, thus promoting antitumor immunity. This can 
be further enhanced by the introduction of immune checkpoint blockade. The MEDIOLA 
study shows synergistic effects of olaparib, durvalumab, and bevacizumab in patients with 
non-germline BRCA-mutated platinum sensitive ovarian cancer [14]. TOPACIO study shows 
promising effects of combination between niraparib and pembrolizumab regardless of BRCA/
homologous recombination deficiency status in platinum-resistant setting [15].
The combination of bevacizumab and a PARPis, together with immune checkpoint blockade 
is a developing area of interest in ovarian cancer. At present, several randomized trials on 
the combination of agents from these three classes are ongoing in the front-line therapy 
of advanced epithelial ovarian cancer, including ENGOT-ov44/FIRST (niraparib, TSR042, 
and bevacizumab), DUO-O (olaparib, durvalumab, and bevacizumab), and ENGOT-ov43/
KEYLYNK-001 (olaparib, pembrolizumab, and bevacizumab). In our study, we focus on 
the combination of olaparib, bevacizumab, and pembrolizumab as maintenance therapy 
after second-line chemotherapy in a platinum-sensitive recurrent setting, specifically in 
BRCA-wildtype patients. It is unknown whether BRCA-wildtype patients could derive clinical 
benefits from olaparib maintenance when combined with other novel agents. We hypothesize 
that olaparib maintenance with bevacizumab and pembrolizumab is synergistic in this 
population. In this study, we aim to evaluate the efficacy and safety of olaparib maintenance 
with bevacizumab and pembrolizumab in BRCA-wildtype patients with platinum-sensitive 
recurrent ovarian cancer.
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